Technology
Health
Biotechnology
Navidea Biopharmaceuticals
$0.13239876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$0.1323
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.0022 (1.69%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell NAVB and other stocks, options, ETFs, and crypto commission-free!
About
Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through the following segments: Diagnostics, Therapeutics, and Corporate. Read More The company was founded in 1983 and is headquartered in Dublin, OH.
Employees
19
Headquarters
Dublin, Ohio
Founded
1983
Market Cap
26.07M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
461.15K
High Today
$0.1347
Low Today
$0.1275
Open Price
$0.1327
Volume
85.29K
52 Week High
$0.4091
52 Week Low
$0.1005
Collections
Technology
Health
Biotechnology
Medical
Therapy
US
North America
News
MarketBeatMar 5
Stock Price, News, & Analysis for Navidea Biopharmaceuticals
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of ...
BusinessWireFeb 28
Navidea Biopharmaceuticals Schedules Fourth Quarter 2018 Earnings Conference Call and Business Update
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or “the Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call on Thursday, March 7th, 2019, at 5:00 pm ET to discuss its financial results for the fourth quarter of 2018 in conjunction with the filing of its annual report on Form 10-K. Jed Latkin, Chief Executive Officer, and Erika Gibson, Director, Finance and ...
Price Paid on Robinhood
49% Lower
Right Now
52 Week Low
$0.1005
Average Price Paid
$0.2595
52 Week High
$0.4091
Earnings
-$0.04
-$0.03
-$0.01
$0.00
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
—
Actual
-$0.02 per share